Association of Eleven Common, Low-Penetrance Colorectal Cancer Susceptibility Genetic Variants at Six Risk Loci with Clinical Outcome

• Janelle M. Hoskins ,

  Contributed equally to this work with: Janelle M. Hoskins, Pei-Shi Ong

  Affiliation Division of Pharmacotherapy and Experimental Therapeutics, Institute for Pharmacogenomics and Individualized Therapy, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America

  ⨯
• Pei-Shi Ong ,

  Contributed equally to this work with: Janelle M. Hoskins, Pei-Shi Ong

  * E-mail: phaops@nus.edu.sg

  Current address: Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore, Singapore.

  Affiliation Division of Pharmacotherapy and Experimental Therapeutics, Institute for Pharmacogenomics and Individualized Therapy, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America

  ⨯
• Temitope O. Keku,

  Affiliation Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America

  ⨯
• Joseph A. Galanko,

  Affiliations Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America, Center for Gastrointestinal Biology and Disease, Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America

  ⨯
• Christopher F. Martin,

  Affiliation Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America

  ⨯
• Clint A. Coleman,

  Current address: Department of Environmental Health Sciences, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana, United States of America.

  Affiliation Division of Pharmacotherapy and Experimental Therapeutics, Institute for Pharmacogenomics and Individualized Therapy, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America

  ⨯
• Michelle Wolfe,

  Affiliation Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America

  ⨯
• Robert S. Sandler,

  Affiliation Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America

  ⨯
• Howard L. McLeod

  Affiliations Division of Pharmacotherapy and Experimental Therapeutics, Institute for Pharmacogenomics and Individualized Therapy, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America, Division of Hematology and Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America, The Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America

  ⨯